UB Paderborn / Katalog / Suche / in CDI

THE MORBIDITY RATE OF GENITOURINARY DISEASES ACCORDING TO THE DATA ON POPULATION RECEIVING MEDICAL CARE IN A MULTIFUNCTIONAL HEALTH CARE FACILITY

Wiadomości lekarskie (1960), 2023, Vol.76 (5 pt 2), p.115-1159

2023

Volltextzugriff (PDF)

HEALTH OF THE ELDERLY PEOPLE AS THE BASIS FOR FORMATION OF MEDICAL AND SOCIAL NEEDS

Wiadomości lekarskie (1960), 2021, Vol.74 (3 cz 2), p.658-664

2021

Volltextzugriff (PDF)

Reducing health inequalities as a component of the health training programs

Wiadomości lekarskie (1960), 2020, Vol.73 (5), p.937-942

2020

Volltextzugriff (PDF)

Patient Characteristics and Medication Treatment Patterns Among Men With Erectile Dysfunction (Ed), Lower Urinary Tract Symptoms Secondary To Benign Prostatic Hyperplasia (Bph-Luts), Or Co-Occurring Ed and Bph-Luts In the Uk Primary Care Setting

Value in health, 2014-11, Vol.17 (7), p.A521-A521

2014

Volltextzugriff (PDF)

Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study

International journal of clinical practice (Esher), 2015-08, Vol.69 (8), p.853-862

2015

Volltextzugriff (PDF)

POS-02.41: Urinary tract infections are uncommon after instalation of intravesical mitomycin C

Urology (Ridgewood, N.J.), 2007, Vol.70 (3), p.244-244

2007

Volltextzugriff (PDF)

OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i036-i037

2022

Volltextzugriff (PDF)

P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i672-i673

2023

Volltextzugriff (PDF)

OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i27-i29

2023

Volltextzugriff (PDF)

DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i088-i089

2022

Volltextzugriff (PDF)

P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i785-i786

2023

Volltextzugriff (PDF)

POS-03.54: Penile fracture: no difference in treatment in two European centres

Urology (Ridgewood, N.J.), 2007, Vol.70 (3), p.288-289

2007

Volltextzugriff (PDF)

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i037-i041

2022

Volltextzugriff (PDF)

DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i090-i091

2022

Volltextzugriff (PDF)

P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i476-i477

2022

Volltextzugriff (PDF)

P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i514-i514

2022

Volltextzugriff (PDF)

P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i373-i374

2022

Volltextzugriff (PDF)

DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i087-i088

2022

Volltextzugriff (PDF)

Matching-adjusted indirect comparison of upadacitinib vs vedolizumab as induction therapy in patients with moderately to severely active ulcerative colitis

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, Vol.38, p.135

2023

Volltextzugriff (PDF)

Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, Vol.117 (10), p.S520

2022

Volltextzugriff (PDF)

PIH99 - Patient Characteristics and Medication Treatment Patterns Among Men With Erectile Dysfunction (Ed), Lower Urinary Tract Symptoms Secondary To Benign Prostatic Hyperplasia (Bph-Luts), Or Co-Occurring Ed and Bph-Luts In the Uk Primary Care Setting

Value in health, 2014-11, Vol.17 (7), p.A521-A521

2014

Volltextzugriff (PDF)

Macromolecular Metal Carboxylates and Their Nanocomposites

1. Aufl., 2010

Volltextzugriff (PDF)

New Onset Epilepsy/Seizure US Nursing Homes and Co-morbidities, 2003-2007

Journal of the American Medical Directors Association, 2011, Vol.12 (3), p.B17-B17

2011

Volltextzugriff (PDF)

MDS Indication of Epilepsy in Elderly Nursing Home Residents

Journal of the American Medical Directors Association, 2009-03, Vol.10 (3), p.B11-B11

2009

Volltextzugriff (PDF)

Depression in Elderly Nursing Home Residents Taking Antiepileptic Medications

Journal of the American Medical Directors Association, 2010, Vol.11 (3), p.B8-B8

2010

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

THE MORBIDITY RATE OF GENITOURINARY DISEASES ACCORDING TO THE DATA ON POPULATION RECEIVING MEDICAL CARE IN A MULTIFUNCTIONAL HEALTH CARE FACILITY

HEALTH OF THE ELDERLY PEOPLE AS THE BASIS FOR FORMATION OF MEDICAL AND SOCIAL NEEDS

Reducing health inequalities as a component of the health training programs

Patient Characteristics and Medication Treatment Patterns Among Men With Erectile Dysfunction (Ed), Lower Urinary Tract Symptoms Secondary To Benign Prostatic Hyperplasia (Bph-Luts), Or Co-Occurring Ed and Bph-Luts In the Uk Primary Care Setting

Patient characteristics and treatment patterns for patients with benign prostatic hyperplasia, erectile dysfunction or co-occurring benign prostatic hyperplasia and erectile dysfunction in general practices in the UK: a retrospective observational study

POS-02.41: Urinary tract infections are uncommon after instalation of intravesical mitomycin C

OP33 Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme

P546 Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison

OP20 The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results

DOP39 Effect of baseline disease characteristics on clinical outcomes in moderate-to-severe Ulcerative Colitis treated with upadacitinib: Results from a Phase 3 trials programme

P658 Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison

POS-03.54: Penile fracture: no difference in treatment in two European centres

OP34 Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis

DOP41 Efficacy and safety of extended induction treatment with upadacitinib 45 mg once daily followed by maintenance upadacitinib 15 or 30 mg once daily in patients with moderately to severely active Ulcerative Colitis

P521 Correlation of histological assessment of mucosal healing with long-term clinical and patient-reported outcomes in patients with moderately to severely active ulcerative colitis treated with upadacitinib: results from the Phase 3 U-ACHIEVE maintenance trial

P573 The safety profile of upadacitinib maintenance therapy in ulcerative colitis in the Phase 3 U-ACHIEVE study is consistent with that in approved indications

P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from, 52-week phase, 3 study U ACHIEVE maintenance

DOP38 Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1

Matching-adjusted indirect comparison of upadacitinib vs vedolizumab as induction therapy in patients with moderately to severely active ulcerative colitis

Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis

PIH99 - Patient Characteristics and Medication Treatment Patterns Among Men With Erectile Dysfunction (Ed), Lower Urinary Tract Symptoms Secondary To Benign Prostatic Hyperplasia (Bph-Luts), Or Co-Occurring Ed and Bph-Luts In the Uk Primary Care Setting

Macromolecular Metal Carboxylates and Their Nanocomposites

New Onset Epilepsy/Seizure US Nursing Homes and Co-morbidities, 2003-2007

MDS Indication of Epilepsy in Elderly Nursing Home Residents

Depression in Elderly Nursing Home Residents Taking Antiepileptic Medications

Suchergebnisse filtern